The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences - Wikidata - wikimedia - TriplyDB

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

http://www.wikidata.org/entity/Q28188518

about

Antioxidants for chronic kidney disease Antihypertensive agents for preventing diabetic kidney disease Antioxidant supplements for preventing gastrointestinal cancers Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases Antioxidant supplements for preventing gastrointestinal cancers Targeting Mitochondria and Reactive Oxygen Species-Driven Pathogenesis in Diabetic Nephropathy Refractory blood pressure in female SHR to increased oxidative stress is not mediated by NO or by upregulation of renal antioxidant enzymes Cardiac and renal function are progressively impaired with aging in Zucker diabetic fatty type II diabetic rats The effects of combined free radical scavenger and sildenafil therapy on age-associated erectile dysfunction: An animal model An almond-enriched diet increases plasma α-tocopherol and improves vascular function but does not affect oxidative stress markers or lipid levels.Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension Hypertension in postmenopausal women.Sex differences in control of blood pressure: role of oxidative stress in hypertension in females Is CaMKII a link between inflammation and hypertrophy in heart?Mitochondrial therapeutics for cardioprotection.Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction.Prediabetes: the importance of early identification and intervention.Valsartan plus hydrochlorothiazide: a review of its use since its introduction.Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease.Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease.Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress?

P2860

Q24198197-A9670568-936F-46FF-B90E-693CAB2553D6 Q24202090-339C612C-9ECA-4C1B-8D47-D23006267B50 Q24242191-DC8C7810-A851-4813-B2D1-52B9E3148C54 Q24242944-9BA42FF7-D23C-45D0-ADEC-0966B871CFD7 Q24245704-A662D2DB-E852-4465-B425-0ED923BED389 Q28083205-60CE6628-BE2F-491D-9D7A-EF33E26D1AFB Q33686567-3142EB96-6932-4333-96A4-300E8B1180BF Q33717027-158FABA4-5130-4C7B-8CBC-5DFFD1CC7CB0 Q34437336-90FD71B8-CF82-4F2F-A59F-2EA604722B31 Q34659813-E4F87FD6-DA33-4798-B9EF-EF48E189EAF9 Q35670580-A1FEE44C-5EF2-41D4-AEA0-530C9C72FCEE Q36082076-B48D9445-1877-44E9-BE6C-3EB00A5494C2 Q36844659-39B29396-8323-458C-A279-609265A38BDF Q37064322-25D52AE9-7150-4D24-8A5F-8AD160B2DA1E Q37152171-D835E68C-6A63-4701-95B1-FE310040A17C Q37433974-126BF94B-502D-46F3-B122-26B411669F27 Q37679215-F5046384-EB75-4756-8071-4A96984EA2BD Q37777010-501EF6FB-AAB9-4D95-B334-A83049DBC3C7 Q37897570-9DDFD7B6-366B-43EA-9E98-B45D4640E914 Q37978891-BB1B9491-5C36-4726-820E-DC853B8EB46B Q38041505-CDE7FA77-5B59-4BEF-A9E0-7BF6C1DE003E Q38165049-2F1BC292-174D-46E5-9BA3-A71CB0F8574F

P2860

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

http://www.wikidata.org/entity/Q28188518

description

2005 թուականին հրատարակուած գիտական յօդուած

@hyw

2005 թվականին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2005

@ast

scientific article (publication date: 2005)

@en

vedecký článok (publikovaný 2005)

@sk

vědecký článek publikovaný v roce 2005

@cs

wetenschappelijk artikel (gepubliceerd in 2005)

@nl

наукова стаття, опублікована у 2005

@uk

مقالة علمية (نشرت عام 2005)

@ar

name

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@ast

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@en

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@nl

type

label

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@ast

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@en

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@nl

prefLabel

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@ast

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@en

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@nl

P1433

Q28188518-7E7DEA4D-9418-49EB-885F-FF369C9AD061

P1476

Q28188518-267DA96D-B497-4003-B11F-A02D554ACA9F

P2093

Q28188518-701B8ABB-9E19-4DF9-A77B-52C239A911CE

Q28188518-A1C853E3-4DB7-4D30-A660-1AEFB492DDB7

Q28188518-A893A024-3DE5-433F-886F-C077F5BAF899

Q28188518-C4E819A6-4535-41E5-8521-DBC9FE7B4EB7

P2860

Q28188518-10A1BF63-2007-4702-92A9-351E2E8CCDD5

Q28188518-17600123-FBEA-4A01-9D95-0D1E1579090E

Q28188518-1BEA0593-EB38-4652-AF68-4BAA4DD723B3

Q28188518-1D653D2F-DC56-4703-9B5C-25E7317C145D

Q28188518-1FCD8843-30F2-4FB5-AA32-B2F3FDEA3077

Q28188518-22987607-56CD-4BE5-A3AF-6313C47618B1

Q28188518-258165E2-D654-42E2-8819-75431870C4BA

Q28188518-2E3AD23C-18F1-41DA-AC99-75D56086CF36

Q28188518-391062A1-67DE-4EDF-B876-FD0CE9248AFC

Q28188518-3F35D9E3-3517-46AF-A5FC-874B1B4FC212

P304

Q28188518-B227352D-2D78-4E74-8EEF-7D9EF04FFC5B

P31

Q28188518-D59DE8A0-8223-4138-BA35-CBDD5D382714

P356

Q28188518-50BB6780-1756-457D-9DBC-0596332C02EC

P407

Q28188518-A1A96B57-12AB-4ED7-A675-140F10DEC25C

P478

Q28188518-E5B5CE78-EDC3-4C88-BB14-47AFEA65EBA9

P50

Q28188518-D3C2273E-B1F5-431D-9780-8D1EA36C6037

P577

Q28188518-5BC035AD-71FA-4E15-B319-BC555D26992C

P698

Q28188518-4667CF57-15FD-4D09-8B3D-3EF8FCC4F3EA

P356

00365510500236366

P1433

The Scandinavian journal of clinical & laboratory investigation. Supplementum

P1476

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

@en

P2093

Bosch J

http://www.w3.org/2001/XMLSchema#string

Lonn E

http://www.w3.org/2001/XMLSchema#string

McQueen MJ

http://www.w3.org/2001/XMLSchema#string

Yusuf S

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review

Cost effectiveness of ramipril treatment for cardiovascular risk reduction

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure?

Vitamin E consumption and the risk of coronary heart disease in men.

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

P304

143-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00365510500236366

http://www.w3.org/2001/XMLSchema#string

P407

P478

240

http://www.w3.org/2001/XMLSchema#string

P50

Hertzel C. Gerstein

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16112972

http://www.w3.org/2001/XMLSchema#string